A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies.

EBioMedicine · 2014 · PMC4292938 · PMID 25599086

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

We found highly significant reductions in Exon 12 index for primary leukemia cells in newly diagnosed high-risk pediatric B-precursor ALL patients. 242 of 279 (87%) leukemic samples had lower CD22ΔE12-index values that were lower than the 95% lower confidence interval for the CD22ΔE12-index values for the normal hematopoietic cells in 74 non-leukemic control bone marrow samples (P < 0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.